nach oben

Journal of Diabetes & Metabolic Disorders

Erschienen in:

27.01.2022 | Research article

Patient preferences for the treatment of type 2 diabetes in Australia: a discrete choice experiment

verfasst von: Akram Ahmad, Muhammad Umair Khan, Parisa Aslani

Erschienen in: Journal of Diabetes & Metabolic Disorders | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Australia has a high proportion of migrants, with an increasing migration rate from India. Type 2 diabetes is a chronic condition common amongst the Indian population. The decision to initiate and continue medication therapy (conventional or ayurvedic medicine) is complex and is influenced by a wide range of factors.

Objective

To determine preferences for conventional vs. ayurvedic medicines in Indian migrants with diabetes, and to identify the factors that may influence their preferences.

Methods

A discrete choice experiment was conducted with participants in Australia who were migrants from India with type 2 diabetes (n=141). Each respondent evaluated eight choice tasks consisting of eight attributes describing medicines and outcomes of medication taking; and were asked to choose ‘conventional’, or ‘ayurvedic’ medicine. A mixed multinomial logit model was used to estimate preferences.

Results

Overall, respondents’ preference to initiate a medicine was negative for both conventional (β=−2.33164, p<0.001) and ayurvedic medicines (β=−3.12181, p<0.001); however, significant heterogenicity was noted in participants’ preferences (SD: 2.33122, p<0.001). Six significant attributes were identified to influence preferences. In decreasing rank order: occurrence of hypoglycaemic events (relative importance, RI=24.33%), weight change (RI=20.00%), effectiveness of medicine (RI=17.91%), instructions to take with food (RI=17.05%), side effects (RI=13.20%) and formulation (RI=7.49%). Respondents preferred to initiate a medicine despite potential side effects.

Conclusions

There was a greater preference for conventional medicine, though neither were preferred. Medicine attributes and medication-taking outcomes influenced people’s preferences for an antidiabetic medicine. It is important to identify individual preferences during healthcare consultations to ensure optimal medication-taking.

IDF Diabetes Atlas-8th edition. International Diabetes Federation. Available from http://www.diabetesatlas.org/. Accessed 26 Jan 2020.

Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besançon S, et al. Global and regional estimates and projections of diabetes-related health expenditure: results from the International Diabetes Federation Diabetes Atlas. Diabet Res Clini Pract. 2020:108072. https://doi.org/10.1016/j.diabres.2020.108072.

Diabetes in Australia. Diabetes Australia, available from; https://www.diabetesaustralia.com.au/diabetes-in-australia. Accessed 26 Jan 2018.

Sainsbury E, Shi Y, Flack J, Colagiuri S. Burden of diabetes in Australia: it’s time for more action. Preliminary report. July 2018. Available from: https://www.sydney.edu.au/content/dam/corporate/documents/faculty-of-medicine-and-health/research/centres-institutes-groups/burden-of-diabetes-its-time-for-more-action-report.pdf. Accessed 16 Mar 2020.

Migration A. Australian Bureau of Statistics, Available from https://www.abs.gov.au/statistics/people/population/migration-australia/latest-release. Accessed 29 Sept 2020.

Centre for Epidemiology and Research. 2002–2005 Report on adult health by country of birth from the New South Wales population health survey. Sydney: New South Wales Department of Health; 2006.

New South Wales Health. The health of the People of New South Wales - Report of the Chief Health Officer 2008. Sydney: New South Wales Department of Health; Population Health Division; 2008.

Pandey MM, Rastogi S, Rawat AK. Indian traditional ayurvedic system of medicine and nutritional supplementation. Evid Based Complement Alternat Med. 2013;12. Article ID 376327. https://doi.org/10.1155/2013/376327.

Alfian SD, Sukandar H, Arisanti N, Abdulah R. Complementary and alternative medicine use decreases adherence to prescribed medication in diabetes patients. J Acupunct Meridian Stud. 2018;11(5):337. https://doi.org/10.1016/j.jams.2018.10.002.CrossRef

10.

Sridharan K. Mohan R, Ramaratnam S. Panneerselvam D. Ayurvedic treatments for diabetes mellitus. Cochrane Database Syst Rev. 2011;12:Art. No.: CD008288. https://doi.org/10.1002/14651858.CD008288.

11.

Steyn M, Couchman L, Coombes G, Earle KA, Johnston A, Holt DW. A herbal treatment for type 2 diabetes adulterated with undisclosed drugs. Lancet. 2018;391(10138):2411. https://doi.org/10.1016/S0140-6736(18)31134-6.CrossRefPubMed

12.

Global Ayurveda S. 2018; Available from http://globalayurvedasummit.com/. Accessed 20 May 2020.

13.

Porqueddu T. Herbal medicines for diabetes control among Indian and Pakistani migrants with diabetes. Anthropol Med. 2017;24(1):17–31. https://doi.org/10.1080/13648470.2016.1249338.CrossRefPubMed

14.

Lawton J, Ahmad N, Hallowell N, Hanna L, Douglas M. Perceptions and experiences of taking oral hypoglycaemic agents among people of Pakistani and Indian origin: qualitative study. BML. 2005;330(7502):1247. https://doi.org/10.1136/bmj.38460.642789.CrossRef

15.

Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–35. https://doi.org/10.1161/CIRCULATIONAHA.108.768986.CrossRefPubMed

16.

Khan MU, Kohn M, Aslani P. The need for a paradigm shift in adherence research: the case of ADHD. Res Social Adm Pharm. 2019;15(3):318–20. https://doi.org/10.1016/j.sapharm.2018.04.033.CrossRefPubMed

17.

Krapek K, King K, Warren SS, George KG, Caputo DA, Mihelich K, Holst EM, Nichol MB, Shi SG, Livengood KB, Walden S. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother. 2004;38(9):1357–62. https://doi.org/10.1345/aph.1D612.CrossRefPubMed

18.

Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299–307. https://doi.org/10.2147/PPA.S106821.CrossRefPubMedPubMedCentral

19.

Arifulla M, John LJ, Sreedharan J, Muttappallymyalil J, Basha SA. Patients’ adherence to anti-diabetic medications in a Hospital at Ajman, UAE. Malaysian J Med Sci. 2014;21(1):44–9.

20.

Abebaw M, Messele A, Hailu M, Zewdu F. Adherence and associated factors towards antidiabetic medication among type II diabetic patients on follow-up at University of Gondar Hospital, Northwest Ethiopia. Adv Nurs. 2016;8579157:2016. https://doi.org/10.1155/2016/8579157.CrossRef

21.

Bagonza J, Rutebemberwa E, Bazeyo W. Adherence to anti diabetic medication among patients with diabetes in eastern Uganda; a cross sectional study. BMC Health Serv Res. 2015;15:168. https://doi.org/10.1186/s12913-015-0820-5.CrossRefPubMedPubMedCentral

22.

Huber CA, Reich O. Medication adherence in patients with diabetes mellitus: does physician drug dispensing enhance quality of care? Evidence from a large health claims database in Switzerland. Patient Prefer Adherence. 2016;10:1803–9. https://doi.org/10.2147/PPA.S115425.CrossRefPubMedPubMedCentral

23.

Rwegerera GM, Moshomo T, Gaenamong M, Oyewo TA, Gollakota S, Mhimbira FA, et al. Antidiabetic medication adherence and associated factors among patients in Botswana; implications for the future. Alex J Med. 2018;54(2):103–9. https://doi.org/10.1016/j.ajme.2017.01.005.CrossRef

24.

Basu S, Garg S, Sharma N, Singh MM, Garg S. Adherence to self-care practices, glycemic status and influencing factors in diabetes patients in a tertiary care hospital in Delhi. World J Diabetes. 2018;9(5):72–9. https://doi.org/10.4239/wjd.v9.i5.72.CrossRefPubMedPubMedCentral

25.

Dhippayom T, Krass I. Medication-taking behaviour in New South Wales Patients with Type 2 Diabetes: an observational study. Aust J Prim Health. 2015;21(4):429–37. https://doi.org/10.1071/PY14062.CrossRefPubMed

26.

Feher MD, Brazier J, Schaper N, Vega-Hernandez G, Nikolajsen A, Bøgelund M. Patients’ with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes. BMJ Open Diabetes Res Care. 2016;4(1). https://doi.org/10.1136/bmjdrc-2016-000192.

27.

Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29:682–9. https://doi.org/10.1111/j.1464-5491.2012.03605.x.CrossRefPubMedPubMedCentral

28.

Seston EM, Ashcroft DM, Griffiths CE. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis. Arch Dermatol. 2007;143(9):1175–9. https://doi.org/10.1001/archderm.143.9.1175.CrossRefPubMed

29.

Sinclair AJ, Alexander CM, Davies MJ, Zhao C, Mavros P. Factors associated with initiation of antihyperglycaemic medication in UK patients with newly diagnosed type 2 diabetes. BMC Endocr Disord. 2012;12(1):1–7. https://doi.org/10.1186/1472-6823-12-1.CrossRefPubMedPubMedCentral

30.

Spoelstra JA, Stolk RP, Klungel OH, Erkens JA, Rutten GE, Leufkens HG. Initiation of glucose-lowering therapy in Type 2 diabetes mellitus patients in general practice. Diabet Med. 2004;21:896–900. https://doi.org/10.1111/j.1464-5491.2004.01273.x.CrossRefPubMed

31.

Mansfield C, Sikirica MV, Pugh A, Poulos CM, Unmuessig V, Morano R, Martin AA. Patient preferences for attributes of Type 2 Diabetes Mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther. 2017;8(6):1365–78. https://doi.org/10.1007/s13300-017-0326-8.CrossRefPubMedPubMedCentral

32.

Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9. https://doi.org/10.2337/dc14-2441.CrossRefPubMed

33.

Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2016 Executive Summary. Endocr Pract. 2016;22(1):84–113. https://doi.org/10.4158/EP151126.CS.CrossRefPubMed

34.

Clark MD, Determann D, Petrou S, Moro D, de Bekker-Grob EW. Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics. 2014;32(9):883–902. https://doi.org/10.1007/s40273-014-0170-x.CrossRefPubMed

35.

Toroski M, Kebriaeezadeh A, Esteghamati A, Karyani AK, Abbasian H, Nikfar S. Patient and physician preferences for type 2 diabetes medications: a systematic review. J Diabetes Metab Disord. 2019;18(2):643–56. https://doi.org/10.1007/s40200-019-00449-4.CrossRefPubMedPubMedCentral

36.

Johnson FR, Lancsar E, Marshall D, Kilambi V, Mühlbacher A, Regier DA, Bresnahan BW, Kanninen B, Bridges JF. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16(1):3–13. https://doi.org/10.1016/j.jval.2012.08.2223.CrossRef

37.

Hair JF, Black WC, Babin BJ, et al. Multivariate Data Analysis: International Edition. 6th ed. New Jersey: Pearson Prentice Hall; 2006.

38.

ChoiceMetrics. Ngene 1.2.1 User Manual & Reference Guide, Australia. 2018.

39.

Rose JM, Bliemer MCJ. Sample size requirements for stated choice experiments. Transportation. 2013;40:1021–41. https://doi.org/10.1007/s11116-013-9451-z.CrossRef

40.

Hensher DA, Greene WH. The mixed logit model: the state of practice. Transportation. 2003;30(2):133–76.CrossRef

41.

Khan MU. Factors influencing medication adherence in people with attention-deficit hyperactivity disorder and their parents/carers (Doctoral dissertation, University of Sydney). 2020.

42.

Orme B. Interpreting the results of conjoint analysis. Getting Started with Conjoint Analyis: Strategies for Product Design and Pricing Research. 2010;2:77–88.

43.

Greene WH. 1951- NLOGIT Reference Guide: Version 3.0. Plainview. NY: Econometric Software, Inc., 2002.

44.

Mühlbacher A, Bethge S. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences. Eur J Health Econom. 2016;17(9):1125–40. https://doi.org/10.1007/s10198-015-0750-5.CrossRef

45.

Aristides M, Weston AR, FitzGerald P, Reun CL, Maniadakis N. Patient preference and willingness-to-pay for Humalog mix 25 relative to humulin 30/70: a multicountry application of a discrete choice experiment. Value Health. 2004;7(4):442–54. https://doi.org/10.1111/j.1524-4733.2004.74007.x.CrossRefPubMed

46.

Gelhorn H, Stringer S, Brooks A, Thompson C, Monz B, Boye K, et al. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK. Diabetes Obes Metab. 2013;15(9):802–9. https://doi.org/10.1111/dom.12091.CrossRefPubMed

47.

Janssen EM, Longo DR, Bardsley JK, Bridges JFP. Education and patient preferences for treating type 2 diabetes: a stratified discrete-choice experiment. Patient Prefer Adherence. 2017;11:1729–36. https://doi.org/10.2147/PPA.S139471.CrossRefPubMedPubMedCentral

48.

Fifer S, Rose J, Hamrosi KK, Swain D. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment. BMC Health Serv Res. 2018;18(1):1–1. https://doi.org/10.1186/s12913-018-3484-0.CrossRef

49.

Mohamed A, Zhang J, Johnson F, Malvoti E, Ostgren C, Parhofer K. The avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: a patient preference study. Value Health. 2013;39(5):397–403. https://doi.org/10.1016/j.diabet.2013.06.001.CrossRef

50.

Hauber AB, Mohamed AF, Johnson FR, Falvey H. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabetic Med. 2009;26(4):416–24. https://doi.org/10.1111/j.1464-5491.2009.02696.x.CrossRefPubMed

51.

Polster M, Zanutto E, McDonald S, Conner C, Hammer M. A comparison of preferences for two GLP-1 products liraglutide and exenatide for the treatment of type 2 diabetes. J Med Econ. 2010;13(4):655–61. https://doi.org/10.3111/13696998.2010.529377.CrossRefPubMed

52.

American Diabetes Association. Glycemic targets. Diabetes Care. 2016;39(Suppl 1):39–46.CrossRef

53.

Bundesa¨rztekammer, Bundesvereinigung K: Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, et al, editors: Nationale Versorgungsleitlinie: Therapie des Typ-2-Diabetes. Kurzfassung. Berlin. 2013.

54.

Ahmad A. Medication-taking behaviour and treatment preferences of Indian migrants with type 2 diabetes in Australia. Doctoral dissertation, The University of Sydney; 2021.

55.

Ranade M, Mudgalkar N. A simple dietary addition of fenugreek seed leads to the reduction in blood glucose levels: A parallel group, randomized single-blind trial. Ayu. 2017;38(1-2):24. https://doi.org/10.4103/ayu.AYU_20915.CrossRefPubMedPubMedCentral

56.

Fenugreek, Diabetes, Diabetes UK. Available from, https://www.diabetes.co.uk/natural-therapies/fenugreek.html. Accessed 18 Dec 2020.

57.

García-Pérez LE, Alvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–94. https://doi.org/10.1007/s13300-013-0034-y.CrossRefPubMedPubMedCentral

Titel: Patient preferences for the treatment of type 2 diabetes in Australia: a discrete choice experiment
verfasst von: Akram Ahmad
Muhammad Umair Khan
Parisa Aslani
Publikationsdatum: 27.01.2022
Verlag: Springer International Publishing
Erschienen in: Journal of Diabetes & Metabolic Disorders / Ausgabe 1/2022
Elektronische ISSN: 2251-6581
DOI: https://doi.org/10.1007/s40200-021-00962-5

Short-term circuit resistance training improves insulin resistance probably via increasing circulating Adropin

Research article

Self-care practice and glycemic Control among type 2 diabetes patients on follow up in a developing country: a prospective observational study

Research article

Amelioration of diabetes and its complications by Manilkara zapota (L) P. Royen fruit peel extract and its fractions in alloxan and STZ-NA induced diabetes in Wistar rats

Research article

Correction to: Metabolic syndrome; Definition, Pathogenesis, Elements, and the Effects of medicinal plants on it’s elements

Correction

COVID-19-specific worries among people with type 2 diabetes following the continuation of the pandemic and occurrence of multiple waves of COVID-19 in Iran

Zur Zeit gratis
COVID-19
Research article

The impact of zinc supplementation on galectin-3 and metabolic markers in diabetic patients on hemodialysis: A randomized, double-blind, placebo-controlled trial

Research article

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

15.01.2025
Melanom
Nachrichten

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Knochenmarktransplantat als Chance für ältere AML-Patienten

15.01.2025
Akute myeloische Leukämie
Nachrichten

Lange Zeit ist die Transplantation von hämatopoetischen Stammzellen nur bei jüngeren Patienten mit akuter myeloischer Leukämie praktiziert worden. Inzwischen profitieren auch Ältere davon. Ergebnisse einer Studie unterstützen dieses Vorgehen.

Nierenzellkarzinom: Kein Nachteil durch subkutan appliziertes Nivolumab

14.01.2025
Nierenkarzinom
Nachrichten

Die subkutane Applikation von Nivolumab ist nach Daten einer Phase-3-Studie ähnlich gut wirksam wie die intravenöse: Die Pharmakokinetik ist vergleichbar, die objektive Response war in der Studie sogar leicht besser als in der Gruppe mit Infusionen.

Vorteile für Androgenentzug plus Androgenrezeptorblockade

14.01.2025
Prostatakarzinom
Nachrichten

Für Männer mit metastasiertem hormonsensitivem Prostata-Ca. (mHSPC), die keine Hormonchemotherapie wollen oder vertragen, ist der Androgenentzug plus Darolutamid eine Alternative: Das Progressionsrisiko wird im Vergleich zum alleinigen Androgenentzug fast halbiert.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Malignes Melanom am Rückens eines 60-jährigen Mannes/© Schadendorf, D. et al. / all rights reserved Springer Medizin Verlag GmbH, Histopathologischer Befund bei akuter myeloischer Leukämie/© National Cancer Institute/cancer.gov, Spritze wird aufgezogen/© scyther5 / Getty Images / iStock, Senior hält Tabletten und Glas Wasser in den Händen/© Andrii Zastrozhnov / Stock.adobe.com (Symbolbild mit Fotomodell), EKG befunden mit System - EKG Essential/© Springer Medizin Verlag GmbH